Evidence map›Paper›PMID 39408938›Full record

ReviewInternational journal of molecular sciences2024

Eloísa Sánchez-Cazorla, Noa Carrera, Miguel Ángel García-González

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Article
  3. Glis3 Is a Modifier of Cyst Progression in Autosomal Dominant Polycystic Kidney Disease.Journal of the American Society of Nephrology : JASN · 2026
    Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Molecular impact of a novelFrontiers in endocrinology · 2026
    Article
  11. Article
  12. Case Report: Identification of aFrontiers in endocrinology · 2026
    Article
  13. Review
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Eloísa Sánchez-CazorlaGroup of Genetics and Developmental Biology of Renal Disease, Laboratory of Nephrology, No. 11, Health Research Institute of Santiago de Compostela (IDIS), Clinical University Hospital (CHUS), 15706 Santiago de Compostela, Spain.ORCID 0009-0002-3767-5020
Noa CarreraGroup of Genetics and Developmental Biology of Renal Disease, Laboratory of Nephrology, No. 11, Health Research Institute of Santiago de Compostela (IDIS), Clinical University Hospital (CHUS), 15706 Santiago de Compostela, Spain.ORCID 0000-0003-0739-0382
Miguel Ángel García-GonzálezGroup of Genetics and Developmental Biology of Renal Disease, Laboratory of Nephrology, No. 11, Health Research Institute of Santiago de Compostela (IDIS), Clinical University Hospital (CHUS), 15706 Santiago de Compostela, Spain.ORCID 0000-0002-4330-7200

Funding

Axencia Galega de Innovacion IN607B 2016/020Axencia Galega de Innovacion IN607B2023/07Federación Española de Enfermedades Raras PI15/01467Federación Española de Enfermedades Raras PI18/0037Federación Española de Enfermedades Raras PI22/00227Instituto de Salud Carlos III RICORS2040 RD21/0005/0020Sociedad Española de Nefrología SEN2021_2
6 · The paper itself

Abstract

The

Indexed as

Hepatocyte Nuclear Factor 1-betaKidneyAnimalsHumansKidney DiseasesMutationHepatocyte Nuclear Factor 1-betaHNF1B protein, human17q12 regionapico-basal polaritycilia developmentcyst formationgene expression regulationHNF1Bintrarenal metabolismnephrogenesisrenal ion transportrenal physiology

Identifiers

PMID39408938
PMCPMC11476927

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.